Loading…
Praxis Precision Medicines, Inc. is projected to rise to $464.16 by 2027, a +30% move from its current price of $357.13. PRAX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $348.14 | $357.41 | $366.92 | +0.08% |
| May 30 | $344.64 | $357.68 | $371.22 | +0.15% |
| May 31 | $342.04 | $357.96 | $374.62 | +0.23% |
| Jun 1 | $339.90 | $358.23 | $377.55 | +0.31% |
| Jun 2 | $338.06 | $358.51 | $380.19 | +0.39% |
| Jun 3 | $336.43 | $358.79 | $382.63 | +0.46% |
| Jun 4 | $334.96 | $359.06 | $384.90 | +0.54% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $334.96 | $359.06 | $384.90 | +0.54% |
| Week 2 | $327.22 | $361.01 | $398.28 | +1.09% |
| Week 3 | $321.80 | $362.96 | $409.38 | +1.63% |
| Week 4 | $317.57 | $364.92 | $419.33 | +2.18% |
| Week 5 | $314.10 | $366.90 | $428.58 | +2.74% |
| Week 6 | $311.15 | $368.88 | $437.33 | +3.29% |
| Week 7 | $308.59 | $370.88 | $445.74 | +3.85% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. Its platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE.
In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc.
and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Praxis Precision Medicines, Inc. trades with the symbol PRAX and is currently priced at $343.56 with a market capitalization of $9.58B. It is ranked 937. The current price sits within a broader technical context, where the near-term picture is supported by bullish sentiment and a 30-day range extending from $286.59 to $411.86.
The ongoing price framework is reinforced by a 50-day simple moving average of $322.26 and a 200-day simple moving average of $223.84, with near-term support at $317.00 and resistance at $350.56.
The long-range outlook shows meaningful upside in the forecast horizon, with the 2026 average price at $343.56 and a 2026 ROI of 0, and increasingly bullish momentum into later years. The multi-year forecast projects a rising trajectory, culminating in a 2050 average price of $6,565.32 with an ROI of 1811 and a bullish sentiment.
A major floor 22.6% below — a decisive break under it would weaken the trend.
The nearest floor, 10.7% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 7.1% above — clearing it would confirm fresh momentum.
Key PRAX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PRAX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $347.49 | Buy | $348.03 | Buy |
| MA 10 | $341.35 | Buy | $343.13 | Buy |
| MA 20 | $336.35 | Buy | $338.28 | Buy |
| MA 50 | $324.43 | Buy | $327.86 | Buy |
| MA 100 | $318.12 | Buy | $302.91 | Buy |
| MA 200 | $226.91 | Buy | $247.15 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.47 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 150.32 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 1.45 | Buy |
| ROC (12) | 8.21 | Buy |
| Bollinger %B (20,2) | 0.98 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.19 | Buy |
| Awesome (5,34) | 12.94 | Buy |
| Ultimate (7,14,28) | 59.66 | Neutral |
| Momentum (10) | 13.93 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 355.19 | Buy |
| ADX (14) | 11.96 | Neutral |
| ATR (14) | 7.87 | Info |
The 30-day picture points to bullish momentum alongside a price around the mid-$300s. RSI14 is 60, and the stock trades above the 50-day moving average of $322.26, while the 200-day moving average sits at $223.84. The immediate price range over the last 30 days runs from $286.59 to $411.86, giving a near-term framework of support near $317.00 and resistance near $350.56.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $272.90 | $357.13 | $491.88 | 0% | Neutral | |
| $369.49 | $464.16 | $616.90 | +30% | Bullish | |
| $448.40 | $578.12 | $795.33 | +62% | Bullish | |
| $588.25 | $775.10 | $1,095.88 | +117% | Bullish | |
| $682.24 | $916.43 | $1,326.05 | +157% | Bullish | |
| $759.88 | $1,038.84 | $1,533.98 | +191% | Bullish | |
| $857.99 | $1,192.35 | $1,793.07 | +234% | Bullish | |
| $892.92 | $1,260.14 | $1,926.67 | +253% | Bullish | |
| $1,000.51 | $1,432.77 | $2,224.30 | +301% | Bullish | |
| $1,193.58 | $1,733.34 | $2,729.38 | +385% | Bullish | |
| $1,855.14 | $2,870.58 | $4,797.93 | +704% | Bullish | |
| $3,892.59 | $6,716.35 | $12,249.57 | +17.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $272.90 | $357.13 | $419.01 | +0.00% |
| June 2026 | $310.58 | $364.44 | $437.58 | +2.05% |
| July 2026 | $323.89 | $383.14 | $466.04 | +5.13% |
| August 2026 | $326.77 | $389.00 | $477.90 | +1.53% |
| September 2026 | $321.71 | $384.99 | $476.82 | -1.03% |
| October 2026 | $326.04 | $392.05 | $489.16 | +1.83% |
| November 2026 | $330.24 | $398.78 | $500.75 | +1.72% |
| December 2026 | $321.13 | $389.35 | $491.88 | -2.37% |
Click any year to see its month-by-month PRAX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The PRAX price prediction for 2026 points to an average of $357.13 (low $272.90, high $491.88) — a potential gain of 0% on today's $357.13. Price action looks broadly range-bound.
In 2027, PRAX is projected to trade between $369.49 and $616.90, averaging $464.16 — a potential gain of +30% from today's $357.13. That is up +30% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Praxis Precision Medicines, Inc.'s 2028 outlook centres on $578.12, within a $448.40 to $795.33 range. That is up +25% on the projected 2027 average. That marks a +62% change versus current levels. Momentum favours further upside here.
By 2029, PRAX could reach as high as $1,095.88, with a base case around $775.10 and support toward $588.25 — roughly +117% from $357.13. Buyers look set to stay in control over this stretch.
Expect PRAX to range from $682.24 to $1,326.05 through 2030. The $916.43 average target implies a +157% move from current prices. That is up +18% on the projected 2029 average. Momentum favours further upside here.
The PRAX price prediction for 2031 points to an average of $1,038.84 (low $759.88, high $1,533.98) — a potential gain of +191% on today's $357.13. Buyers look set to stay in control over this stretch.
In 2032, PRAX is projected to trade between $857.99 and $1,793.07, averaging $1,192.35 — a potential gain of +234% from today's $357.13. That is up +15% on the projected 2031 average. Momentum favours further upside here.
Praxis Precision Medicines, Inc.'s 2033 outlook centres on $1,260.14, within a $892.92 to $1,926.67 range. That is up +6% on the projected 2032 average. That marks a +253% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, PRAX could reach as high as $2,224.30, with a base case around $1,432.77 and support toward $1,000.51 — roughly +301% from $357.13. Momentum favours further upside here.
Expect PRAX to range from $1,193.58 to $2,729.38 through 2035. The $1,733.34 average target implies a +385% move from current prices. That is up +21% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The PRAX price prediction for 2040 points to an average of $2,870.58 (low $1,855.14, high $4,797.93) — a potential gain of +704% on today's $357.13. Momentum favours further upside here.
In 2050, PRAX is projected to trade between $3,892.59 and $12,249.57, averaging $6,716.35 — a potential gain of +17.8x from today's $357.13. That is up +134% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in PRAX today (≈ 2.800101 PRAX) could be worth
$18,806.46
+$17,806.46 (+1781%) by 2050 · US Dollar
Based on the average projected PRAX price of $6,716.35 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PRAXwould be worth at today's price.
$1,000 invested in PRAX on May 27, 2025 (≈ 27.700832 PRAX) would be worth
$9,892.8
+$8,892.8 (+889.3%) today · 9.89× · US Dollar
Based on a PRAX entry price of $36.1 vs. today's $357.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $335.61 | $1,064.12 | +6.4% |
| 1 month ago | $330.99 | $1,078.98 | +7.9% |
| 3 months ago | $340.47 | $1,048.93 | +4.9% |
| 6 months ago | $196.46 | $1,817.83 | +81.8% |
| 1 year ago | $36.1 | $9,892.8 | +889.3% |
| All time (5.0y) ago | $296.1 | $1,206.11 | +20.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PRAX forecast.
Our base-case forecast reaches $710.00 around 2029.
Implied market cap at $710.00: $19.79B
The year-by-year forecast shows neutral sentiment for 2026, with a min of $272.90, an avg of $343.56, and a max of $472.37, and a 0% ROI. From 2027 onward the outlook turns bullish, with rising averages and meaningful upside. Notable milestones include 2027 avg $450.33, 2028 avg $561.42, 2029 avg $751.52, and 2030 avg $897.06 with an ROI of 161.1.
By 2031 the avg is projected to $1,012.42 and by 2032 to $1,158.05, continuing higher through 2033 at $1,230.43 and 2034 at $1,391.17, then 2035 at $1,693.53. The forecast shows continued upside in the later years, with 2040 avg $2,811.64 and an ROI of 718.4, and 2050 avg $6,565.32 with an ROI of 1811 and a bullish sentiment. The 2030, 2040, and 2050 figures illustrate substantial upside potential, but these are estimates, not guarantees, and depend on a range of factors affecting CNS therapies and related trials.
Tap a question to reveal the answer.
The 2030 forecast shows an avg of $897.06, with a min of $662.31 and a max of $1,310.60, and an ROI of 161.1% with a bullish sentiment.
The long-range outlook is bullish from 2027 onward, with a 2030 avg of $897.06 and an ROI of 161.1%, though these figures are estimates and not guarantees.
The forecast for 2030 lists a max of $1,310.60, and 2031 max $1,510.56, 2032 max $1,760.77, and 2033 max $1,903.15, indicating potential to exceed $1,000 in the projection window.
Current price is $343.56 and market cap is $9.58B.
The 30-day range is $286.59–$411.86 with RSI 60.0; SMA50 is $322.26 and SMA200 is $223.84, with near-term support at $317.00 and resistance at $350.56.
Praxis Precision Medicines, Inc. Community Discussion
0Share your Praxis Precision Medicines, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.